Martina Schmittnaegel

发表

Rapid activation of tumor-associated macrophages boosts preexisting tumor immunity

Y. Kienast, C. Ries, O. Ast, 2018, The Journal of experimental medicine.

Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade

Y. Kienast, A. Kiialainen, Michele De Palma, 2017, Science Translational Medicine.

Macrophage depletion induces edema through release of matrix-degrading proteases and proteoglycan deposition

C. Ries, I. Klaman, T. Petrova, 2021, Science Translational Medicine.

Optimized antiangiogenic reprogramming of the tumor microenvironment potentiates CD40 immunotherapy

Y. Kienast, C. Klein, C. Ries, 2019, Proceedings of the National Academy of Sciences.

Reprogramming Tumor Blood Vessels for Enhancing Immunotherapy.

Michele De Palma, Martina Schmittnaegel, 2017, Trends in cancer.

Activation of cytomegalovirus-specific CD8+ T-cell response by antibody-mediated peptide-major histocompatibility class I complexes

C. Klein, Martina Schmittnaegel, V. Levitsky, 2015, Oncoimmunology.

T cell–induced CSF1 promotes melanoma resistance to PD1 blockade

G. Coukos, Esther Danenberg, N. Wald, 2018, Science Translational Medicine.

Distinct cDC subsets co-operate in CD40 agonist response while suppressive microenvironments and lack of antigens subvert efficacy

L. Boon, C. Ries, S. Janssens, 2021, bioRxiv.

Overcoming microenvironmental resistance to PD-1 blockade in genetically engineered lung cancer models

I. Keklikoglou, C. Ries, E. Meylan, 2021, Science Translational Medicine.

Targeting CSF1R Alone or in Combination with PD1 in Experimental Glioma

G. Tabatabai, M. Tatagiba, C. Ries, 2021, Cancers.

A New Class of Bifunctional Major Histocompatibility Class I Antibody Fusion Molecules to Redirect CD8 T Cells

C. Klein, G. Georges, E. Hoffmann, 2016, Molecular Cancer Therapeutics.

Title : A new class of bifunctional major histocompatibility class I antibody fusion molecules to redirect CD 8 T cells

C. Klein, G. Georges, E. Hoffmann, 2016 .

Committing Cytomegalovirus-Specific CD8 T Cells to Eliminate Tumor Cells by Bifunctional Major Histocompatibility Class I Antibody Fusion Molecules

C. Klein, G. Georges, O. Mundigl, 2015, Cancer Immunology Research.

CD40 Agonist Restores the Antitumor Efficacy of Anti-PD1 Therapy in Muscle-Invasive Bladder Cancer in an IFN I/II-Mediated Manner

D. Speiser, C. Ries, G. Verdeil, 2020, Cancer Immunology Research.

Vaccine-induced CD8 T cells are redirected with peptide-MHC class I-IgG antibody fusion proteins to eliminate tumor cells in vivo

C. Klein, R. Kroczek, F. Herting, 2020, mAbs.